Merck, Stallergenes race to FDA with new allergy treatments

Merck and Stallergenes are preparing to approach the FDA with two new therapies that promise to replace the traditional allergy shot with sub-lingual treatments that would be a lot easier to take as well as safer to dispense. "It takes probably three years, at least, of immunotherapy to produce a good and lasting result," Dr. Harold Nelson, an allergist at National Jewish Health in Denver, tells the Los Angeles Times. "An awful lot of people get tired of it." And in rare cases, usually...